Insulin biosimilar (SemBioSys/Tasly)
胰岛素生物类似药 (SemBioSys/Tasly)
Report date: 2023/02/13 15:20:10
Base Information
Drug NameInsulin biosimilar (SemBioSys/Tasly)
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesSembiosysTasly Pharmaceuticals Inc
China Registration ClassN/A
Develop Information
Active CompaniesN/A
Inactive CompaniesSembiosysTasly Pharmaceuticals Inc
Active IndicationsN/A
Inactive Indications
Other Information
ATC Code +[5]
Related LinksN/A